Raymond James analyst Martin Auster initiated coverage of Ascendis Pharma (ASND) with a Strong Buy rating and $271 price target The firm sees “a high conviction path” to 2035 total revenues of about $4.6B – including $3.3B for Yorvipath for hypoparathyroidism, $750M for TransCon CNP for achondroplasia and $550M for Skytrofa – as well as “a range of credible upside scenarios,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Grants Employee Warrants to Boost Engagement
- Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald
- Ascendis Pharma Submits EMA Application for Achondroplasia Treatment
- Ascendis Pharma submits TransCon CNP marketing authorization application to EMA
- Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation